Hepatitis C is a major risk factor for the development of hepatocellular carcinoma (HCC), arising typically on a background of liver cirrhosis. Treatment of hepatitis C has been revolutionized by the addition of oral direct-acting antivirals (DAAs) with sustained virological response (SVR) rates above 90%. There is a recent concern under debate about the increased risk of early HCC recurrence in patients with chronic hepatitis C who were treated with direct-acting antivirals. Nonetheless, these reports mostly focused on patients who were cirrhotic and were already treated for HCC. We report 4 cases of treatment naive, chronic hepatitis C patients who were treated with DAAs and rapidly developed infiltrative HCC despite achieving SVR. Moreover, in our scenario, one of the patients appeared clinically non-cirrhotic until he developed HCC.
Introduction
Chronic Hepatitis C virus (HCV) infected patients with advanced fibrosis/chronic liver disease (CLD) have an overall annual risk of 3.2% for the development of hepatocellular carcinoma (HCC) [1] . Antiviral therapy has been available since the early 1990s. However, the SVR rates were unsatisfactory with interferon-based regimens particularly when advanced liver disease sets in [2] .
Also, the side effect profile of interferon limits its use due to poor compliance [3] . Addition of direct-acting antivirals (DAAs) in the armamentarium has increased the HCV cure rates well above 90% even in patients with bridging fibro-sis or cirrhosis, with the additional advantage of avoiding side effects related with interferon. The occurrence of HCC is distinctly less in patients with cirrhosis who achieve sustained virological response (SVR) as compared to those who do not. However, this risk is not completely eliminated even after HCV remedy.
There are case reports describing patients diagnosed with HCC up to 13 and even 20 years after successful antiviral therapy with interferon [4] [5] . Out of 500 patients treated with direct-acting antivirals (DAAs) from 2014 to 2017 at the Aga Khan University Hospital, Karachi, we present 4 cases with the rapid development of HCC even after achieving SVR with DAAs, of which all were treatment naive, while one appeared clinically non-cirrhotic until the development of HCC.
Case 1
A 64-year-old male was found to be HCV antibody positive on routine screening in November 2014. He was asymptomatic and physical examination was unremarkable. On investigations complete blood count (CBC) showed hemoglobin admitted with encephalopathy, ascites and hepatorenal syndrome. Due to the guarded prognosis, he was kept for comfort care. Since there was no clinical improvement, the family took the patient home for the end of life care.
Case 2
A 74-year-old hypertensive female was found to be HCV In June 2017, she presented with nausea and weight loss. On examination, she had hepatomegaly with ascites. Repeat ultrasound due to recent onset ascites revealed multiple hypoechoic lesions in the liver, largest measuring 1.5 × 1.2 cm.
Triphasic CT scan showed cirrhotic liver with multicentric HCC in right lobe having an infiltrative pattern, 12 × 9 cm in size, inseparable from the gallbladder.
The right branch of the portal vein was thrombosed. Few lymph nodes were also seen near porta hepatis along with multiple soft tissue nodules in the lung suggestive of metastasis. Moderate ascites and multiple varices were also seen. Her AFP was 1100 IU/ml.
Due to the advance BCLC stage of HCC, options for treatment were very limited. After a detailed discussion with the patient and family members, she was kept on supportive care only.
Case 3
A 42-year-old gentleman with a history of diabetes and hypertension came for evaluation of melena in June 2014. On workup, he was found to have HCV related CLD with grade-III esophageal varices for which he underwent band ligation. He follow-up.
Discussion
Eradication of HCV plays a key role in the prevention of HCC. A pooled analysis of 25,497 patients from 12 studies confirms that achievement of SVR reduces the risk of HCC (hazard ratio, 0.24 [95% CI, 0.18 -0.31]; p = 0.001), with absolute risk reduction of 4.6% in patients achieving SVR (95% CI, 4.2% -5.0%) [6] . Nonetheless, the risk of HCC persists many years after SVR especially in high-risk patient i.e. those with established cirrhosis, old age, and diabetes. Consequently, they require surveillance for HCC despite SVR [7] . A few years back, DAAs were introduced in conjunction with interferon and ribavirin to promote their antiviral potential [8] [9] . Later they completely replaced interferon and ribavirin due to their better tolerance, even in older age group and cirrhotic patients, along with better safety profile, and are now considered the first line agents for HCV treatment [10] [11] [12] . However, data on long-term outcomes in cirrhotic patients treated with DAAs is still lacking.
A recent "note of caution" was provided by Reig et al. who interestingly showed an increased incidence of HCC with early recurrence after eradication of HCV with interferon-free therapy after successfully treated liver cancer (16 of 58 patients, 28%) [13] . This postulate the idea that HCV elimination using DAAs may induce changes in the inflammatory status and immune response to tumors, leading to early recurrence. It is also hypothesized that DAA may enhance the growth of tiny/invisible HCC due to dysregulation of the immune system. This phenomenon is in contrast to interferon treatment which has its own immune-modulatory and anti-proliferative action [14] .
Natural killer (NK) cells are the most prevalent innate immune cells in the liver. Chronic HCV infection is known to cause activation of NK cells along with increased expression of interferon-stimulated genes, hence enhancing the intrahepatic immune response. This intrahepatic immune activation is lost in patients treated with DAAs [15] [16] . Changes leading to liver regeneration which is associated with cure of inflammation and change in immunologic status can Open Journal of Gastroenterology be responsible for the evolution of precancerous lesions into frank malignancy [17] [18] . However, none of the three cohorts of French prospective multicenter ANRS showed an increase in HCC recurrence after DAA treatment in patients who underwent curative HCC therapies [21] . This was supported by English data where the author showed a reduction in HCC rate from 4% in untreated patients to 1.9% in patients with virus eradication, over 6 and 9 months respectively [22] .
There is no head to head comparison except a retrospective analysis in patients who achieved SVR after interferon/ribavirin treatment vs DAAs treatment showing similar 3 and 5 year cumulative HCC development rates in both groups (1% and 2.2% in Interferon group, and 1.3% and 3% in DAA, respectively) [23] . Reig et al. also raised concern about the pattern of tumor recurrence in patients treated with DAA [13] , supported by another Italian cohort of cirrhotic patients who develop infiltrative patterns of HCC [25] .
One of our patients was unique in that he achieved SVR and he appeared non-cirrhotic till he developed HCC a year after successful DAA therapy. In all of our patients, there was a rapid development of HCC, supported by recent negative imaging before the actual diagnosis. At the time of diagnosis, the tumor appeared infiltrative on CT scan with portal vein thrombosis making it advance staged. On follow up scan involvement of whole liver parenchyma within 3 months in case 1 also supports the speediness of tumor growth. This supports the concern raised by Reig and Roman in their group of patients. This also suggests that patients treated for HCV, despite being non-cirrhotic, should be kept in surveillance even after achieving SVR [26] . Due to the typical finding of tumor on CT scan, a biopsy was not done in any of the above patients.
In conclusion, there is a debatable increased risk of HCC occurrence/early recurrence in patients treated with DAAs. Our case series supports the existing data about the pattern of HCC occurrence after DAA therapy; however, large prospective studies are needed to solve this mystery.
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